Trial Profile
A Phase III, Randomized, Double-blind, Double-dummy, Multi-center Clinical Study to Observe the Efficacy and Safety of Febuxostat Compared with Allopurinol in Subjects with Hyperuricemia (Including Gout)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Nov 2016
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary) ; Allopurinol
- Indications Gout; Hyperuricaemia
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma; Teijin Pharma
- 11 Mar 2015 Status changed from recruiting to completed as reported by Japan Pharmaceutical Information Center - Clinical Trials Information.
- 24 Jan 2014 New trial record